146 related articles for article (PubMed ID: 12626127)
1. Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts.
Takano S; Tsuboi K; Matsumura A; Nose T
Neuro Oncol; 2003 Jan; 5(1):1-7. PubMed ID: 12626127
[TBL] [Abstract][Full Text] [Related]
2. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
3. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
[TBL] [Abstract][Full Text] [Related]
4. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
[TBL] [Abstract][Full Text] [Related]
5. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
Borgström P; Gold DP; Hillan KJ; Ferrara N
Anticancer Res; 1999; 19(5B):4203-14. PubMed ID: 10628376
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
7. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production.
Fusetti L; Pruneri G; Gobbi A; Rabascio C; Carboni N; Peccatori F; Martinelli G; Bertolini F
Cancer Res; 2000 May; 60(9):2527-34. PubMed ID: 10811135
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption.
Rubenstein JL; Kim J; Ozawa T; Zhang M; Westphal M; Deen DF; Shuman MA
Neoplasia; 2000; 2(4):306-14. PubMed ID: 11005565
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo.
Borgström P; Bourdon MA; Hillan KJ; Sriramarao P; Ferrara N
Prostate; 1998 Apr; 35(1):1-10. PubMed ID: 9537593
[TBL] [Abstract][Full Text] [Related]
11. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.
Asano M; Yukita A; Suzuki H
Jpn J Cancer Res; 1999 Jan; 90(1):93-100. PubMed ID: 10076571
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
Kim KJ; Li B; Winer J; Armanini M; Gillett N; Phillips HS; Ferrara N
Nature; 1993 Apr; 362(6423):841-4. PubMed ID: 7683111
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
Melnyk O; Zimmerman M; Kim KJ; Shuman M
J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
Gabrilovich DI; Ishida T; Nadaf S; Ohm JE; Carbone DP
Clin Cancer Res; 1999 Oct; 5(10):2963-70. PubMed ID: 10537366
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
16. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development.
Hong YK; Chung DS; Joe YA; Yang YJ; Kim KM; Park YS; Yung WK; Kang JK
Clin Cancer Res; 2000 Aug; 6(8):3354-60. PubMed ID: 10955823
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
18. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.
Borgström P; Hillan KJ; Sriramarao P; Ferrara N
Cancer Res; 1996 Sep; 56(17):4032-9. PubMed ID: 8752175
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft.
Matsumoto K; Konno H; Tanaka T; Baba M; Kanai T; Kamiya K; Ohba K; Nakamura S
Jpn J Cancer Res; 2000 Jul; 91(7):748-52. PubMed ID: 10920283
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
